Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Noah Heftler

Dermatology New York, NY Medical Doctor

NPI 1346376696 CMS profile 106793

150 E 58Th St, 4Th Floor Annex, New York, NY 10155

Open in the dashboard

General payments

$7,382

214 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Noah Heftler of New York, NY is reported in the CMS Open Payments database as having received $7,382 across 214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,393 28
2024 General $1,499 39
2023 General $1,387 35
2022 General $1,125 34
2021 General $507 24
2020 General $634 24
2019 General $836 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Noah Heftler
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Noah Heftler were reported at $1,393. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Noah Heftler Dermatology median Middle half National median
2019 $836 $454 $129–$1,240 $163
2020 $634 $235 $81–$756 $114
2021 $507 $377 $108–$1,108 $132
2022 $1,125 $514 $143–$1,391 $149
2023 $1,387 $607 $159–$1,674 $160
2024 $1,499 $751 $204–$1,903 $164
2025 $1,393 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,662 52 payments
  2. Lilly USA, LLC $1,454 42 payments
  3. UCB, Inc. $577 12 payments
  4. Janssen Biotech, Inc. $542 13 payments
  5. Galderma Laboratories, L.P. $479 12 payments
  6. Novartis Pharmaceuticals Corporation $459 14 payments
  7. Incyte Corporation $354 12 payments
  8. E.R. Squibb & Sons, L.L.C. $278 6 payments
  9. Genzyme Corporation $269 6 payments
  10. Amgen Inc. $229 9 payments
  11. Other $1,080 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,366 213 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $962 25 payments
  2. TALTZ $843 33 payments
  3. Bimzelx $519 10 payments
  4. TREMFYA $496 7 payments
  5. SKYRIZI $495 17 payments
  6. OLUMIANT $432 6 payments
  7. OPZELURA $354 12 payments
  8. SOTYKTU $278 6 payments
  9. DUPIXENT $269 6 payments
  10. HUMIRA $262 13 payments
  11. Other $2,925 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

260

Median for Dermatology: 534

Drug cost

$5,332

Median for Dermatology: $67,151

Branded share of claims

11.2%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 29 $1,604
Hydrocortisone Generic 40 $947
Fluocinonide Generic 21 $809
Ketoconazole Generic 41 $599
Clindamycin Phosphate Generic 15 $483
Triamcinolone Acetonide Generic 69 $476
Doxycycline Hyclate Generic 18 $221
Mupirocin Generic 27 $193

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$37,303

Medicare's payments for the services billed

Medicare patients

161

Average age 76

Services billed

807

56 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 54%
Arthritis 37%
Diabetes 27%
Ischemic heart disease 26%
Cancer 22%
Osteoporosis 18%
Atrial fibrillation 15%
Chronic kidney disease 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $426
$426 — —
Bimzelx
  • UCB, Inc. $318
$318 — —
OLUMIANT
  • Lilly USA, LLC $273
$273 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $109
$109 — —
SKYRIZI
  • AbbVie, Inc. $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record